ER negative

The results were ER negative, PgR positive, HER2 negative, and Ki-67 25%. As the prognosis and treatment of invasive lobular carcinoma was unclear, caution was required.

After surgery, adjuvant chemotherapy with trastuzumab and pertuzumab was administered...After surgery, chemotherapy with trastuzumab deruxtecan was administered. Eight months later, the lung metastases have disappeared, and the patient is currently under observation. We report a case of pancreatic metastasis following breast cancer surgery.

The efficacy of perioperative treatment with pembrolizumab for early-stage triple-negative breast cancer(TNBC)at high risk of recurrence was demonstrated in the KEYNOTE-522 trial, and it's indication was expanded in Japan as of September 2022...As follow-up continued, CEA levels began to decline and the thymic enlargement showed a tendency to regress. These findings suggest a potential association between immune checkpoint inhibitor and thymic enlargement, as well as a possible link to the observed CEA elevation.

Following completion of weekly paclitaxel(PTX), initiation of epirubicin plus cyclophosphamide(EC)resulted in a marked platelet decrease to 1.3×104/μL on day 7, necessitating repeated platelet transfusions. These findings suggest that in breast cancer patients with ITP, neoadjuvant chemotherapy may not be feasible, and primary surgical intervention should be considered. Furthermore, when administering EC, vigilant hematological monitoring is imperative.

Histopathological examination revealed that they were non-caseating granulomas without any evidence of malignancy, consistent with a diagnosis of sarcoid-like reaction. The patient has been followed up postoperatively without recurrence for 12 months.

Adjuvant chemotherapy may optimize survival in select patients with T1b-T2N0M0 MBC, though prospective validation is warranted.

P1, N=15, Recruiting, Xiaorong Sun

The current findings identified miR-4330 restoration as a tool for overcoming acquired drug resistance and reducing cancer activity, which might be used to improve therapeutic strategies and treatment regimens for breast cancer patients. miR-4330 may be useful as a diagnostic and prognostic marker for drug-resistant breast cancer.

This first national analysis provides real-world evidence that PMRT utilization in Switzerland remains low, with underuse in high-risk patients and selective, biologically informed escalation in intermediate-risk disease. While patterns reflect evolving multidisciplinary care, persistent gaps in ASCO-ASTRO-SSO guideline implementation underscore the need for continued surveillance and individualized, risk-adapted PMRT decision-making.

P2, N=442, Terminated, Palleos Healthcare GmbH | Completed --> Terminated; The trial stopped recruitment prematurely after a first planned interim analysis of the first 100 pCR results (given that a probability of less than 2.5% of meeting the primary endpoint was estimated).

Thus, all three markers of PD-L1 expression are associated with the characteristics of aggressive BC, demonstrating moderate concordance between the tests.

This study identified CLIC6 as a novel gene associated with radioresistance in ER+/HER2- breast cancer and showed that theaflavin functions as a natural radiosensitizer in a CLIC6-dependent manner, consistent with its high-affinity interaction with CLIC6. Targeting CLIC6 may provide a promising strategy to enhance radiotherapy efficacy in this common breast cancer subtype.